STAGES Trial: Study of Adiposity, Growth and Endocrine Stages
The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2012 by University of Utah.
Recruitment status was Recruiting
Information provided by (Responsible Party):
Nicole L. Mihalopoulos, University of Utah
First received: October 25, 2011
Last updated: June 1, 2012
Last verified: June 2012
The investigators propose to conduct a cross-sectional study of 60 participants who are 18-30 years of age to undergo research PET/CT. The purpose of this study is to investigate the relationships between Brown Adipose Tissue (BAT), the adiponectin/leptin (A/L) ratio, and components of the metabolic syndrome in young adults.
||Observational Model: Cohort
Time Perspective: Cross-Sectional
||Changes in Adipokines and Adiposity During Puberty and Young Adulthood
Primary Outcome Measures:
- Presence of brown adipose tissue [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Presence of metabolic dysfunction [ Time Frame: 2 years ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||April 2013 (Final data collection date for primary outcome measure)
We propose to conduct a cross-sectional study of 60 participants who are 18-30 years of age to undergo research PET/CT. The purpose of this study is to investigate the relationships between Brown Adipose Tissue (BAT), the adiponectin/leptin (A/L) ratio, and components of the metabolic syndrome in young adults. This study is part of a larger study aimed at understanding the mechanism of brown adipose tissue as a potential protective factor against metabolic dysfunction.
|Ages Eligible for Study:
||18 Years to 30 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Healthy, obese young adults
- Males and females, 18-30 years of age at enrollment, who are obese (BMI greater or equal to 30 kg/m2, weight less than 159 kg) and healthy
- Without medications and endocrine/genetic disorders known to affect weight.
- Participants may have insulin resistance, impaired glucose tolerance, dyslipidemia, or hypertension.
- Anyone who refuses participation.
- A genetic syndrome or other endocrine disorder known to cause obesity (Prader-Willi, Cushing Syndrome, Leptin deficiency, etc.).
- Use of the following medications: psychotropics, sulphonylurea, thiazolidinediones, insulin, glucocorticoids, anti-neoplastic agents, angiotensin receptor blocker, angiotensin-converting enzyme inhibitors.
- Pregnancy or history of pregnancy.
- Active infectious disease
- History of CVD or stroke during the previous 36 months
- Total cholesterol 300 mg/dl, triglycerides 400 mg/dl
- Blood pressure 140/90 mmHg
- Fasting plasma glucose 126 mg/dl.
- Diabetes mellitus, type 1 or 2.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01460784
University of Utah
||University of Utah, Department of Pediatrics, Division of Adolescent Medicine
No publications provided
||Nicole L. Mihalopoulos, Associate Professor of Pediatrics, University of Utah
History of Changes
|Other Study ID Numbers:
|Study First Received:
||October 25, 2011
||June 1, 2012
||United States: Institutional Review Board
Keywords provided by University of Utah:
Brown adipose tissue
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on July 26, 2014
Signs and Symptoms